



**THE CHINESE UNIVERSITY OF HONG KONG
FACULTY OF MEDICINE
SCHOOL OF BIOMEDICAL SCIENCES**

SBS PI Seminar Series 2023-2024

Prof. TONG Man Carol

Assistant Professor

School of Biomedical Sciences

Faculty of Medicine, The Chinese University of Hong Kong

will present a seminar entitled

“Understanding tumor-intrinsic mechanisms which direct therapy resistance in liver cancer”

Hepatocellular carcinoma (HCC) is an aggressive liver malignancy with limited therapeutic options. Tyrosine kinase inhibitors (TKI) and immune checkpoint inhibitors (ICI) are the integral part of systemic therapy in advanced hepatocellular carcinoma (HCC). Despite various TKI and ICI-based therapies are approved for first-line and second-line treatment in HCC, the response rates of patients to these therapies are still limited. For HCC patients who progress on first-line TKI, second-line ICI-based therapy targeting PD-1 or CTLA-4 is generally followed, based on the principle that second-line drugs with distinct mechanisms of action from first-line drugs are anticipated to generate better/optimal therapeutic effect in the sequential treatment. However, a compromised therapeutic efficacy of first-line TKI followed by second-line ICI-based therapy has been witnessed in cancer patients. In this seminar, we will share our recent endeavours in understanding the tumor-intrinsic mechanisms that attenuate the efficacy of TKI-ICI sequential therapy in HCC.

29 February 2024, Thursday, 4:00 pm– 5:00 pm

Room G02, Lo Kwee-Seong Integrated Biomedical Sciences Building,

Area 39, The Chinese University of Hong Kong

